<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501433</url>
  </required_header>
  <id_info>
    <org_study_id>17-603</org_study_id>
    <nct_id>NCT03501433</nct_id>
  </id_info>
  <brief_title>Effects of Nicotinamide Riboside on Metabolism and Vascular Function</brief_title>
  <official_title>Effects of Nicotinamide Riboside on Metabolism and Vascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iowa State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iowa State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Nicotinamide Riboside (NR)
      supplementation on metabolism and vascular function following high-fat meal. Differences
      between young (18-35) and older (60-75) adults will be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effects of 7 days of Nicotinamide Riboside (NR)
      or placebo supplementation on metabolism and vascular function following high-fat meal.
      Differences between young (18-35) and older (60-75) adults will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, cross-over</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>I single investigator will be responsible for blinding. All researchers involved in collection and evaluation of data will remain blinded to treatments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NAD+</measure>
    <time_frame>7 days</time_frame>
    <description>Blood and peripheral blood mononuclear cell (PBMC) levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vasodilatory responsiveness</measure>
    <time_frame>7 days</time_frame>
    <description>Post-Occlusion Reactive Hyperemia (PORH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipdemia</measure>
    <time_frame>7 days</time_frame>
    <description>Fasting and postprandial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress and inflammation</measure>
    <time_frame>7 days</time_frame>
    <description>Plasma markers and expression in circulating PBMCs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aging</condition>
  <condition>Lipemia</condition>
  <arm_group>
    <arm_group_label>Nicotinamide Riboside Chloride (Niagen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days of placebo supplementation (2/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide riboside chloride (Niagen)</intervention_name>
    <description>250 mg capsules 2x/day for 7 days</description>
    <arm_group_label>Nicotinamide Riboside Chloride (Niagen)</arm_group_label>
    <other_name>Nicotinamide Riboside, Niagen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2x/day for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 35 (young) and 60 to 75 (older)

          -  Normo- or pre-hypertensive (blood pressure &lt;140/90 mmHg)

          -  Non-smokers

          -  Able to give informed consent and participate in all laboratory visits

        Exclusion Criteria:

          -  Currently taking any medications that could interfere with cardiovascular or metabolic
             outcomes will be excluded from the study (e.g., beta-blockers)

          -  Known metabolic (e.g. Type I or Type II diabetes, cardiovascular disease, etc.) or
             immunologic (e.g. HIV, cancer, autoimmune, etc.) diseases

          -  Food allergies to egg, milk, soy or wheat

          -  Women who are pregnant or planning to become pregnant during the course of the study,

          -  Pacemaker or other implanted device

          -  Unwilling to participate in the experimental protocol or blood draws will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudy Valentine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iowa State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rudy Valentine, PhD</last_name>
    <phone>515-294-3867</phone>
    <email>rvalenti@iastate.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Iowa State University</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudy Valentine, Ph.D.</last_name>
      <phone>515-294-3867</phone>
      <email>rvalenti@iastate.edu</email>
    </contact>
    <investigator>
      <last_name>Rudy Valentine, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iowa State University</investigator_affiliation>
    <investigator_full_name>Rudy Valentine</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>postpandial</keyword>
  <keyword>lipemia</keyword>
  <keyword>microvascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

